On August 7, Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (HENGRUI PHARMA) responded to investor inquiries on its interactive platform, stating that since its A-share listing in 2000, the company raised approximately 467 million yuan through its initial public offering.
Since its debut on the Shanghai Stock Exchange in 2000, the company has consistently rewarded shareholders through measures such as stock dividends. To date, cumulative cash dividends paid on A-shares total about 10.6 billion yuan, significantly exceeding the amount raised from the A-share market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments